Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2009-2016

  Jekunen, Antti ^a  

^a Vaasa Oncology Clinic   (Finland)

Author keywords

Clinical oncology; Company organization; Decision making; Drug development; Pipeline; Portfolio; Portfolio analysis; Product management

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG QUALITY; DRUG RESEARCH; FINANCIAL MANAGEMENT; INFORMATION PROCESSING; ONCOLOGY; PATENT; QUALITY CONTROL PROCEDURES; ANIMAL; HUMAN; MARKETING; MEDICAL RESEARCH; MEDICINAL CHEMISTRY; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ANIMALS; BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; DECISION MAKING; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MARKETING; PHARMACEUTICAL PREPARATIONS;

EID: 84908299604     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S68579     Document Type: Article

References (34)

1. Garvin DA, Roberto M. What you don’t know about making decisions. Harv Bus Rev. 2001;79(8):108–116.
2. Skrepnek GH, Sarnowski JJ. Decision-making associated with drug candidates in the biotechnology research and development (R&D) pipeline. J Comm Biotech. 2007;13:99–110.
3. Krishnan V, Ulrich KT. Product development decisions: a review of the literature. Manage Sci. 2001;47(1):1–21.
4. Hultink EJ, Griffin A, Hart S, Robben HS. Industrial new product launch strategies and product development performance. J Prod Innovat Manag. 1997;14(4):243–257.
5. Gassmann O, Reepmeyer G. Organizing pharmaceutical innovation: from science-based knowledge creator to drug-oriented knowledge brokers. Creativ Innov Manage. 2005;14(3):233–245.
6. Needleman P. From a twinkle in the eye to a blockbuster drug. Res Tech Manage. 2001;44(6):38–41.
7. Chan T, Nickerson JA, Owan H. Strategic management of R&D pipelines with cospecialized investments and technology markets. Manage Sci. 2007;53(4):667–682.
8. George ED, Farid SS. Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications. Biotechnol Prog. 2008;24(3):698–713.
9. Albertini S, Butler J. R&D networks in pharmaceutical company: some implications for human resource management. R&D Manage. 1995; 25(4):377–393.
10. Kuhlmann J. The applications of biomarkers in early clinical drug development to improve decision-making processes. Ernst Schering Res Found Workshop. 2007;(59):29–45.
11. Bakker A, Caricasole A, Gaviraghi G, et al. How to achieve confidence in drug discovery and development: managing risk (from a reductionist to a holistic approach). Chem Med Chem. 2009;4(6):923–933.
12. Raynor ME. The Strategy Paradox: Why Committing to Success Leads to Failure (and What to Do About It). New York: Random House Digital; 2007.
13. Adler PS, Mandelbaum A, Nguyen V, Schwere E. From project to process management: an empirically based framework for analyzing product development time. Manage Sci. 1995;41(3):458–484.
14. Lam MD. Knowing when to pull the plug on your experimental drug: how to succeed by failing faster. Pharmaceut Exec. 2004;3:55–60.
15. Blau GE, Pekny JF, Varma VA, Bunch PR. Managing a portfolio of interdependent new product candidates in the pharmaceutical industry. J Prod Innov Manage. 2004;21:227–245.
16. Ding M, Eliashberg J. Structuring the new product development pipeline. Manage Sci. 2002;48(3):343–363.
17. Jekunen AP, Pauwels EK, Kairemo KJ. Microdosing in early lead discovery. Bioanalysis. 2010;2(3):421–428.
18. Chen C, Sun L, Li CL. Evaluation of early efficacy endpoints for proof-of-concept trials. J Biopharm Stat. 2013;23(2):413–424.
19. Bower JL, Gilbert CG. From Resource Allocation to Strategy. New York: Oxford University Press; 2005.
20. Cooper RG, Edgett SJ, Kleinschmidt EJ. Portfolio Management for New Products. 2nd ed. Cambridge, MA: Perseus Publishing; 2001.
21. Elmquist M, Segrestin B. Towards a new logic for front end management: from drug discovery to drug design in pharmaceutical R&D. Creativ Innov Manage. 2007;16(2):106–120.
22. Krishnan V, Gupta S. Appropriateness and impact of platform-based product development. Manage Sci. 2001;47(1):52–68.
23. Sanwal A. Optimizing Corporate Portfolio Management: Aligning Investment Proposals with Organizational Strategy. Hoboken, NJ: John Wiley and Sons; 2007.
24. Murphy PL. Pharmaceutical project management – is it different? Project Manage J. 1989;3:35–38.
25. Graves SB, Rinquest JL, Case RH. Formulating optimal R&D portfolios. Res Tech Manage. 2000;43(3):47–51.
26. Patel NR, Ankolekar S, Antonijevic Z, Rajicic N. A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk. Stat Med. 2013;32(10): 1763–1777.
27. Girotra K, Terwiesch C, Ulrich KT. Valuing R&D projects in a portfolio: evidence from the pharmaceutical industry. Manage Sci. 2007;53(9): 1452–1466.
28. Hernàndez-Cuevas C. Collaborative innovation: the future of BioPharma. J Technol Manage Innov. 2007;2(3):1–3.
29. Rajapakse A, Titchener-Hooker NJ, Farid SS. Modelling of the biopharmaceutical drug development pathway and portfolio management. Comput Chem Eng. 2005;29:1357–1368.
30. Vuorinen I. Project evaluation methods for R&D portfolio management. Tampereen yliopisto, Laskentatoimi, Seminaaritutkielma; 2005.
31. Jacob WF, Kwak YH. In search of innovative techniques to evaluate pharmaceutical R&D projects. Technovation. 2003;23(4):291–296.
32. Renko M. Market orientation in markets for technology – evidence from biotechnology ventures. Turku School of Economics. 2006; Series A-8.
33. Tiggemann RF, Dworaczyk DA, Sabel H. Project portfolio management: a powerful strategic weapon in pharmaceutical drug development. Drug Inf J. 1998;32(3):813–824.
34. Rajegopal S, McGuin P, Waller J. Project Portfolio Management: Leading the Corporate Vision. New York: Palgrave Macmillan; 2007.